Volume 16, Issue 6 (November & December 2025)
BCN 2025, 16(6): 1067-1080 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bavafa A, Sepehrinezhad A, Gorji A, Forouzanfar F, Sahab-Negah S. Protocol Optimization for Exosome Production From Umbilical Cord Mesenchymal Stem Cells: A Step Toward Clinical Translation. BCN 2025; 16 (6) :1067-1080
URL: http://bcn.iums.ac.ir/article-1-3236-en.html
URL: http://bcn.iums.ac.ir/article-1-3236-en.html
1- Neuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. & Department of Neuroscience, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
2- Department of Neuroscience, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. & Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran. & Department of Neurosurgery, Epilepsy Research Center, Münster University, Münster, Germany.
3- Department of Neuroscience, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. & Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
2- Department of Neuroscience, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. & Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran. & Department of Neurosurgery, Epilepsy Research Center, Münster University, Münster, Germany.
3- Department of Neuroscience, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. & Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Abstract:
Introduction: Exosomes, nano-scale extracellular vesicles, hold transformative potential in regenerative medicine and neurodegenerative disease treatment. However, inconsistent isolation methods, contamination risks, and lack of standardization impede clinical translation. This study aimed to introduce a protocol, guided by the minimal information for studies of extracellular vesicles (MISEV) guidelines, for isolating high-concentration exosomes from human umbilical cord mesenchymal stem cells (UC-MSCs).
Methods: UC-MSCs were expanded in alpha-minimum essential medium (MEM) with 10% fetal bovine serum (FBS), followed by serum-free conditioning. Phenotypic characterization via flow cytometry confirmed CD90/CD44 positivity and CD45/CD11b negativity. Exosomes were isolated via differential centrifugation, filtration, and dual ultracentrifugation. Characterization was performed using transmission electron microscopy (TEM), dynamic light scattering (DLS), bicinchoninic acid (BCA) assay, and western blot analysis for CD9 and CD63, with calnexin as a negative control.
Results: TEM confirmed exosome integrity with spherical or cup-shaped morphology and intact bilayers. DLS showed a monodisperse population (121.3±23.7 nm, polydispersity index [PDI] <0.3) and stable zeta potential (−37.3 to −43.8 mV). The BCA assay quantified exosomal protein at 1098.2 μg/mL, surpassing conventional yields. Western blotting confirmed expression of CD9 and CD63 and absence of calnexin, indicating minimal contamination.
Conclusion: This standardized, reproducible protocol produces therapeutic-grade UC-MSC exosomes with high structural fidelity and colloidal stability, aligning with MISEV criteria. Although scalability remains a challenge, this method provides a critical foundation for translational studies. Future studies should prioritize functional assays in neurodegenerative models, cargo profiling, and comparative analyses with other MSC sources. This study advances exosome research toward clinical-grade applications, bridging gaps in regenerative medicine and therapeutic development.
Methods: UC-MSCs were expanded in alpha-minimum essential medium (MEM) with 10% fetal bovine serum (FBS), followed by serum-free conditioning. Phenotypic characterization via flow cytometry confirmed CD90/CD44 positivity and CD45/CD11b negativity. Exosomes were isolated via differential centrifugation, filtration, and dual ultracentrifugation. Characterization was performed using transmission electron microscopy (TEM), dynamic light scattering (DLS), bicinchoninic acid (BCA) assay, and western blot analysis for CD9 and CD63, with calnexin as a negative control.
Results: TEM confirmed exosome integrity with spherical or cup-shaped morphology and intact bilayers. DLS showed a monodisperse population (121.3±23.7 nm, polydispersity index [PDI] <0.3) and stable zeta potential (−37.3 to −43.8 mV). The BCA assay quantified exosomal protein at 1098.2 μg/mL, surpassing conventional yields. Western blotting confirmed expression of CD9 and CD63 and absence of calnexin, indicating minimal contamination.
Conclusion: This standardized, reproducible protocol produces therapeutic-grade UC-MSC exosomes with high structural fidelity and colloidal stability, aligning with MISEV criteria. Although scalability remains a challenge, this method provides a critical foundation for translational studies. Future studies should prioritize functional assays in neurodegenerative models, cargo profiling, and comparative analyses with other MSC sources. This study advances exosome research toward clinical-grade applications, bridging gaps in regenerative medicine and therapeutic development.
Keywords: Exosomes, Mesenchymal stem cells (MSCs), Ultracentrifugation, Regenerative medicine, Neurodegenerative diseases, Translational research
Type of Study: Original |
Subject:
Cellular and molecular Neuroscience
Received: 2025/05/30 | Accepted: 2025/07/30 | Published: 2025/11/28
Received: 2025/05/30 | Accepted: 2025/07/30 | Published: 2025/11/28
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
